StreetInsider

• Log in to your account:

  
  Log in
• Signup
• Home
• EPS Insider
• Event Calendar
• Conferences
• Classic Site

Upgrade to SI Premium - Free Trial

Biogen (BIIB)

Biogen (BIIB) PT Raised to $250 at TD Cowen October 21, 2026 3:45 AM - StreetInsider RBC Capital names top healthcare stocks as sector upgraded to overweight October 20, 2026 4:05 PM - StreetInsider Biogen (BIIB) PT Raised to $310 at Wells Fargo October 20, 2026 6:25 AM - StreetInsider Biogen to present Empaveli long-term data at ASN Kidney Week October 19, 2026 7:30 AM - StreetInsider Biogen to Present New Data Across Nephrology Portfolio, Including Long-term EMPAVELI® (pegcetacoplan) Phase 3 Results, at American Society of Nephrology (ASN) Kidney Week October 19, 2026 7:30 AM - StreetInsider Biogen (BIIB) PT Raised to $220 at BMO Capital October 12, 2026 9:53 AM - StreetInsider Truist Securitas's Biotechnology Earnings Preview: 'INSM, BBIO, NBIX Most Levered to the Print' October 12, 2026 9:04 AM - StreetInsider JPMorgan gets bullish on Biogen ahead of 2027 catalysts October 12, 2026 7:27 AM - StreetInsider JPMorgan Upgrades Biogen (BIIB) to Overweight October 12, 2026 2:29 AM - StreetInsider Biogen (BIIB) PT Raised to $270 at UBS October 9, 2026 9:06 AM - StreetInsider CCB Int'l Starts Biogen (BIIB) at Outperform October 9, 2026 5:37 AM - StreetInsider Biogen (BIIB) PT Lowered to $256 at RBC Capital October 8, 2026 8:26 AM - StreetInsider Form 4 BIOGEN INC. For: Oct 01 Filed by: Godbout Sean October 5, 2026 5:01 PM - SEC Filing Stoke Therapeutics meets with FDA on Dravet syndrome drug NDA October 5, 2026 7:00 AM - StreetInsider Stoke Therapeutics Announces Completion of Successful Meeting with the FDA to Align on Planned U.S. NDA for Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome October 5, 2026 7:00 AM - BizWire Biogen reports 52-week phase 2 data for lupus skin drug litifilimab October 2, 2026 11:20 AM - StreetInsider Biogen’s Litifilimab Demonstrates Rapid and Durable Efficacy in New 52-Week Phase 2 Data from Ongoing Phase 2/3 AMETHYST Study, Reinforcing Its Potential as a First-in-Class Therapy for Cutaneous Lu October 2, 2026 11:20 AM - StreetInsider Stoke Therapeutics adds Bo Cumbo to its board of directors September 23, 2026 4:02 PM - StreetInsider Stoke Therapeutics Appoints Bo Cumbo to its Board of Directors, Enhancing Commercial Expertise as the Company Advances Zorevunersen Development Toward Potential FDA Approval and Commercialization September 23, 2026 4:01 PM - BizWire Biogen's Empaveli cuts proteinuria 75% in teens with rare kidney disease September 17, 2026 4:15 PM - StreetInsider Phase 3 Pediatric EMPAVELI Data Published in Clinical Journal of the American Society of Nephrology Show Reduction in Proteinuria and Stabilized Kidney Function in Adolescents with C3G or Primary IC-M September 17, 2026 4:15 PM - StreetInsider Biogen (BIIB) Reiterated at Buy by Stifel After Investor Meeting September 10, 2026 7:39 AM - StreetInsider Biogen (BIIB) PT Raised to $175 at HSBC September 10, 2026 3:28 AM - StreetInsider A Micro-Cap Biotech Just Cleared a Milestone Most Never Reach September 8, 2026 8:30 AM - StreetInsider Stoke, Biogen share 4-year data on zorevunersen for Dravet syndrome September 4, 2026 6:00 AM - StreetInsider Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16t September 3, 2026 7:30 PM - StreetInsider Biogen (BIIB) PT Raised to $245 at Piper Sandler September 3, 2026 7:59 AM - StreetInsider Stoke, Biogen to present 4-year zorevunersen data at epilepsy congress September 1, 2026 7:30 AM - StreetInsider Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Cong September 1, 2026 7:30 AM - StreetInsider This biotech stock still Wolfe's top pick as multiple catalysts loomh August 31, 2026 8:00 AM - StreetInsider Raymond James: 'We now believe that 12 of the top 20 pharma companies have selected Veeva CRM' August 25, 2026 8:33 AM - StreetInsider Biogen (BIIB) PT Raised to $260 at RBC Capital, 'Deep Dive Suggests Upcoming Liti SLE Data Could Start I&I Buildout On Right Path' August 25, 2026 6:36 AM - StreetInsider Eisai, Biogen launch subcutaneous Leqembi autoinjector in the U.S. August 24, 2026 8:01 AM - StreetInsider Eisai, Biogen launch subcutaneous Leqembi autoinjector in the U.S. August 24, 2026 8:01 AM - StreetInsider LEQEMBI IQLIK®(lecanemab-irmb) Autoinjector for Initiation of Therapy Now Available in the U.S. for Early Alzheimer's Disease August 24, 2026 8:00 AM - PR NewsWire Biogen (BIIB) call put ratio 3.7 calls to 1 put with a focus on September calls August 20, 2026 4:50 AM - StreetInsider Wolfe Research upgrades Biogen, AbbVie on pipeline strength and valuation August 13, 2026 9:26 AM - StreetInsider Wolfe Research Upgrades Biogen (BIIB) to Outperform August 13, 2026 5:38 AM - StreetInsider Form 3 BIOGEN INC. For: Aug 03 Filed by: Parini Michael August 12, 2026 4:51 PM - SEC Filing Biogen completes acquisition of RayThera in immunology push August 6, 2026 6:15 PM - StreetInsider Biogen Completes Acquisition of RayThera Inc. August 6, 2026 6:15 PM - StreetInsider Form SCHEDULE 13G/A BIOGEN INC. Filed by: FMR LLC August 6, 2026 10:18 AM - SEC Filing Form 4 BIOGEN INC. For: Aug 03 Filed by: Minor Lloyd August 5, 2026 4:04 PM - SEC Filing Stoke Therapeutics to Present at the Canaccord Genuity 46th Annual Growth Conference August 5, 2026 8:00 AM - BizWire Form 144 BIOGEN INC. Filed by: Minor Lloyd August 4, 2026 11:23 AM - SEC Filing Biogen (BIIB) PT Raised to $241 at Mizuho August 4, 2026 6:39 AM - StreetInsider Stoke Therapeutics Announces Second Quarter 2026 Financial Results and Provides Business Updates August 3, 2026 4:01 PM - BizWire Form 144 BIOGEN INC. Filed by: Minor Lloyd August 3, 2026 1:02 PM - SEC Filing Biogen (BIIB) PT Raised to $251 at H.C. Wainwright July 31, 2026 6:44 AM - StreetInsider Biogen (BIIB) PT Raised to $240 at UBS July 30, 2026 9:29 AM - StreetInsider Biogen (BIIB) PT Raised to $225 at TD Cowen July 30, 2026 9:10 AM - StreetInsider Biogen (BIIB) PT Raised to $208 at BMO Capital July 30, 2026 9:04 AM - StreetInsider Biogen (BIIB) PT Lowered to $240 at RBC Capital July 30, 2026 8:32 AM - StreetInsider Biogen (BIIB) PT Raised to $231 at Morgan Stanley July 30, 2026 8:13 AM - StreetInsider Biogen (BIIB) PT Raised to $248 at Canaccord July 30, 2026 7:20 AM - StreetInsider Guggenheim Reiterates Buy Rating on Biogen (BIIB) July 30, 2026 6:42 AM - StreetInsider Oppenheimer Reiterates Outperform Rating on Biogen (BIIB) July 29, 2026 1:51 PM - StreetInsider Biogen (BIIB) call put ratio 1.7 calls to 1 put into quarter results July 29, 2026 11:15 AM - StreetInsider Biogen Q2 revenue, adjusted EPS beat estimates as growth portfolio lifts sales July 29, 2026 6:47 AM - StreetInsider Form 10-Q BIOGEN INC. For: Jun 30 July 29, 2026 6:37 AM - SEC Filing Form 8-K BIOGEN INC. For: Jul 29 July 29, 2026 6:10 AM - SEC Filing Biogen (BIIB) Tops Q2 EPS by 43c, Beats on Revenue; Offers FY26 EPS Guidance July 29, 2026 6:07 AM - StreetInsider Biogen (BIIB) PT Raised to $200 at Barclays July 29, 2026 5:19 AM - StreetInsider Biogen (BIIB) call put ratio 1 call to 1 put into quarter results July 28, 2026 11:15 AM - StreetInsider Stoke Therapeutics to Host Webcast and Conference Call to Discuss Second Quarter 2026 Business and Financial Updates July 27, 2026 4:01 PM - BizWire Full Article List